Compare EXP & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXP | NUVL |
|---|---|---|
| Founded | 1963 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 7.8B |
| IPO Year | 1994 | 2021 |
| Metric | EXP | NUVL |
|---|---|---|
| Price | $173.11 | $95.29 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 15 |
| Target Price | ★ $226.44 | $135.33 |
| AVG Volume (30 Days) | 400.7K | ★ 446.7K |
| Earning Date | 01-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.56% | N/A |
| EPS Growth | ★ 1.18 | N/A |
| EPS | ★ 11.21 | N/A |
| Revenue | ★ $495,023,000.00 | N/A |
| Revenue This Year | $1.84 | N/A |
| Revenue Next Year | $1.69 | $1,064.25 |
| P/E Ratio | $15.83 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $175.59 | $55.54 |
| 52 Week High | $243.64 | $113.02 |
| Indicator | EXP | NUVL |
|---|---|---|
| Relative Strength Index (RSI) | 21.01 | 37.09 |
| Support Level | N/A | $73.22 |
| Resistance Level | $239.71 | $107.13 |
| Average True Range (ATR) | 5.68 | 3.48 |
| MACD | -2.66 | -0.45 |
| Stochastic Oscillator | 2.54 | 8.83 |
Eagle Materials Inc produces and sells construction products and building materials. Construction products include cement, slag, concrete, and aggregates and building materials include cement and gypsum wallboard, and are sold to the construction and building industries. The firm organizes itself into two sectors: Heavy Materials, which includes the Cement and Concrete and Aggregates segments, and Light Materials, which includes the Gypsum Wallboard and Recycled Paperboard segments.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.